SCHEMBL6861832

SCHEMBL6861832

COC(=O)/C=C/c1ccc2c(c1)CCC(C(=O)O)O2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.53
ALDH1A1 P00352 3/20 0.53
TTR P02766 1/20 0.46
APP P05067 1/20 0.46
PTPN1 P18031 1/20 0.44
EPHX2 P34913 1/20 0.43
P2RY6 Q15077 1/20 0.43
NFKB1 P19838 1/20 0.43
NFKB2 Q00653 1/20 0.43
RELA Q04206 1/20 0.43
CA12 O43570 1/20 0.43
CA1 P00915 1/20 0.43
CA2 P00918 1/20 0.43
TYR P14679 1/20 0.43
CA7 P43166 1/20 0.43
CA9 Q16790 1/20 0.43
CA14 Q9ULX7 1/20 0.43
JAK2 O60674 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6861842 1.00 KDM4E (0.53) KDM4EALDH1A1TTRAPPPTPN1
SCHEMBL6855472 0.79 CYP4F2 (0.43) ALDH1A1NFKB1NFKB2RELACYP4F2
SCHEMBL30970352 0.77 KDM4E (0.64) KDM4EALDH1A1TTRAPPPTPN1
SCHEMBL7296313 0.76 PPARG (0.51) ALDH1A1NFKB1NFKB2RELACYP4F2
SCHEMBL7296319 0.76 PPARG (0.51) ALDH1A1NFKB1NFKB2RELACYP4F2
SCHEMBL433940 0.74 CYP4F2 (0.50) NFKB1NFKB2RELASMN1; SMN2CYP4F2
SCHEMBL15990431 0.73 FFAR1 (0.53) KDM4EALDH1A1TTRAPPPTPN1
SCHEMBL17391702 0.73 FFAR1 (0.53) KDM4EALDH1A1TTRAPPPTPN1
SCHEMBL4193774 0.72 ESR1 (0.56) NFKB1NFKB2RELACYP4F2CYP4A11
SCHEMBL7290410 0.72 ESR1 (0.56) NFKB1NFKB2RELACYP4F2CYP4A11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6797714-B2 HYPOGLYCEMIC AGENTS; ANTIDIABETIC AGENTS; SIDE EFFECT REDUCTION BAYER PHARMACEUTICALS CORPORATION 2004-09-28 US disclosed
US-20030013705-A1 Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists BAYER PHARMACEUTICALS CORPORATION 2003-01-16 US disclosed
US-6469031-B1 USEFUL IN THE TREATMENT OF CONDITIONS SUCH AS HYPER-TRIGLYCERIDAEMIA, HYPERCHOLESTEROLAEMIA AND IN LOWERING HIGH DENSITY LIPOPROTEIN LEVELS AS WELL AS IN THE TREATMENT OF ATHEROSCLEROTIC, CARDIOVASCULAR AND DIABETIC CONDITIONS BAYER CORPORATION 2002-10-22 US disclosed
EP-1040106-B1 CARBOXYL SUBSTITUTED CHROMAN DERIVATIVES USEFUL AS BETA 3 ADRENORECEPTOR AGONISTS BAYER AG (US) 2002-08-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013705-A1 Novel carboxyl substituted chroman derivatives useful as beta 3 adrenoreceptor agonists ADRB3, ADRB1, ADRB2 KDM4E 3162/4885ALDH1A1 1345/4885TTR 3801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.